Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 7Genitourinary 3Sarcoma 2Gastrointestinal 2Breast 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1CNS 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Melanoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 44Cyclophosphamide 21Nivolumab 18fludarabine 10durvalumab 8Paclitaxel 8Magnetic Resonance Spectroscopy 8Interleukin-2 8Docetaxel 8aldesleukin 7Radiosurgery 7Ipilimumab 7spartalizumab 6poly ICLC 6fludarabine phosphate 6atezolizumab 6Specimen Handling 6Radiotherapy 6Carboplatin 6cemiplimab 5Drug Therapy 5Cisplatin 5Biopsy 5Temozolomide 4Immune Checkpoint Inhibitors 4tremelimumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 3pazopanib 3avelumab 3Trastuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × bempegaldesleukin × Breast × Clear all
NCT02983045 2023-03-13

PIVOT-02

Nektar Therapeutics

Phase 1/2 Completed
557 enrolled 22 charts
BreastDermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03435640 2023-03-08

REVEAL

Nektar Therapeutics

Phase 1/2 Terminated
64 enrolled 22 charts
BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Recurrence, Sarcoma, Colorectal Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡